4 quarters tracked · Beat rate 75% · Updated quarterly
| Period | Report Date | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|---|
| Q1 2026 | 2026-03-31 | $0.48 | $0.56 | +17.0% | Beat |
| Q4 2025 | 2025-12-31 | $0.66 | $0.45 | -32.1% | Miss |
| Q3 2025 | 2025-09-30 | $0.58 | $0.61 | +5.3% | Beat |
| Q2 2025 | 2025-06-30 | $0.45 | $0.48 | +6.8% | Beat |
Earnings Beat Rate
Dexcom has beaten analyst EPS estimates in 3 of 4 tracked quarters (75% beat rate). Data sourced from SEC filings and analyst consensus. View full AI analysis →